Alterations of the biomarker S-100B and NSE in patients with acute vertebral spine fractures

Wolf, Harald; Krall, Christoph; Pajenda, Gholam; Leitgeb, Johannes; Bukaty, Adam; Hajdu, Stefan; Sarahrudi, Kambiz

doi:10.1016/j.spinee.2014.04.027

Cited by 23 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measurement of S100β 397 has potential as an acute marker of SCI, as it is significantly increased in the blood (76,77,81) and 398 CSF (76) of rats at 6h after severe contusion injury compared to sham injury. In the human acute 399 setting (<48h), S100β is also increased in the serum of patients with vertebral spine fractures (mean=0.77 μg/L; n=34) compared to uninjured patients (0.14 μg/L; n=29) (78) …”

mentioning

confidence: 97%

“…Both types of injury tissue damage and include neurofilaments (NF) (9), Tau (10), neuron specific enolase (NSE) (11), 137 S100 calcium-binding protein β (S100β) (11) and glial fibrillary acidic protein (GFAP) (9). These 138 tissue specific biomarkers (discussed in greater detail below) hold great promise as they are typically 139 released into the CSF then taken up into the blood stream, allowing for their detection local to the 140 injury site and systemically.…”

mentioning

confidence: 99%

“…Again, in humans NSE has only been assessed in the acute 380 period post-injury (≤24h) (9,78) and measurement outside of this timeframe may be inappropriate 381 with respect to the short half-life of this protein. and plasma showed significantly greater levels of NSE in moderately and severely injured rats (with 386 greater NSE levels in the severely vs. moderately injured) compared to mildly injured animals (77).…”

mentioning

confidence: 99%

See 2 more Smart Citations

The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood

Fuller

et al. 2016

Spinal Cord

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 97%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood

Fuller

et al. 2016

Spinal Cord

View full text Add to dashboard Cite

show abstract

“…Ahadi et al (2015) recently found that also serum NSE levels were significantly higher during the first 48 hours after injury in the 26 traumatic SCI patients included in the study compared to the control group [19]. In a population of 34 patients with vertebral spine fractures, however, the analysis of NSE levels revealed no significant difference [20].…”

Section: Neuron-derived Biomarkersmentioning

confidence: 90%

“…S100B is a dimeric calcium-binding protein localized predominantly in astroglial and Schwann cells and is the most intensively studied marker in SCI. Both serum and CSF levels of S100B are elevated in SCI patients [22,20,18,28]. The concentration of S100B was significantly higher in patients with a motor complete injury compared to patients with motor incomplete injury [18,22].…”

Section: Glial-derived Biomarkersmentioning

confidence: 91%

The Next Generation of Biomarker Research in Spinal Cord Injury

et al. 2016

View full text Add to dashboard Cite

In traumatic spinal cord injury (SCI) patients, the assessment of the exact degree of lesion severity and neurological prognosis has proven to be extremely challenging. The current tools for predicting functional outcome in SCI patients such as clinical examination and magnetic resonance imaging are often inaccessible to unstable or polytraumatized patients, lack sensitivity, and are unreliable in the acute phase of the injury. Multiple candidate protein biomarkers known to be linked to the pathology have been studied for their potential to predict neurological outcome over time. This hypothesis-driven approach, however, has yielded only minimal success, and the reported individual markers lack sensitivity and correlation with specific outcome measures, which highlights the need for an unbiased high-throughput screening approach to identify novel candidate biomarkers. Antibodies were suggested to represent better biomarkers as their counterpart antigens, as they are highly specific and abundantly present in blood due to their inherent amplification and long half-life. Moreover, antibodies are easily accessible and are amenable to high-throughput screening. We therefore suggest an unbiased, high-throughput, and powerful antibody profiling procedure, named Serological antigen selection, based on complementary DNA (cDNA) phage display to combine the multiple benefits of stable and frequent antibodies and those of an unbiased method. The application of such an innovative and unbiased approach can complement the more traditional approaches to aid in the discovery of novel SCI-associated biomarkers.

show abstract

Prognosticating acute traumatic spinal cord injury using Neurofilament (NF), Neuron Specific Enolase (NSE), Matrix Metalloproteinases (MMPs), and S-100B as biomarkers

Paragond,

Dhatt,

Kumar

et al. 2023

Ir J Med Sci

View full text Add to dashboard Cite

Alterations of the biomarker S-100B and NSE in patients with acute vertebral spine fractures

Cited by 23 publications

References 20 publications

The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood

The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood

The Next Generation of Biomarker Research in Spinal Cord Injury

Prognosticating acute traumatic spinal cord injury using Neurofilament (NF), Neuron Specific Enolase (NSE), Matrix Metalloproteinases (MMPs), and S-100B as biomarkers

Contact Info

Product

Resources

About